Cargando…

Characterization and quantitation of fluorescent Gag virus-like particles

Detalles Bibliográficos
Autores principales:	Gutiérrez-Granados, Sonia, Cervera, Laura, Gòdia, Francesc, Segura, María Mercedes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980646/ http://dx.doi.org/10.1186/1753-6561-7-S6-P62

Ejemplares similares

Gag Virus-like Particles Functionalized with SARS-CoV-2 Variants: Generation, Characterization and Recognition by COVID-19 Convalescent Patients’ Sera
por: Boix-Besora, Arnau, et al.
Publicado: (2023)

Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
por: Boix-Besora, Arnau, et al.
Publicado: (2022)

Differential N‐ and O‐glycosylation signatures of HIV‐1 Gag virus‐like particles and coproduced extracellular vesicles
por: Lavado‐García, Jesús, et al.
Publicado: (2022)

An Alternative Perfusion Approach for the Intensification of Virus-Like Particle Production in HEK293 Cultures
por: Lavado-García, Jesús, et al.
Publicado: (2020)

Quality Assessment of Virus-Like Particles at Single Particle Level: A Comparative Study
por: González-Domínguez, Irene, et al.
Publicado: (2020)

A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles
por: González-Domínguez, Irene, et al.
Publicado: (2021)

Corrigendum: An Alternative Perfusion Approach for the Intensification of Virus-Like Particle Production in HEK293 Cultures
por: Lavado-García, Jesús, et al.
Publicado: (2021)

P10-10. HIV-1 Gag virus like particles pseudotyped with CD40 ligand to stimulate innate immune responses
por: Köstler, J, et al.
Publicado: (2009)

Production of virus-like particles for vaccines
por: Fuenmayor, J., et al.
Publicado: (2017)

Optimization of HEK 293 cell growth by addition of non-animal derived components using design of experiments
por: Cervera, Laura, et al.
Publicado: (2011)

Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus
por: Fontana, Diego, et al.
Publicado: (2021)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

At‐line multi‐angle light scattering detector for faster process development in enveloped virus‐like particle purification
por: Pereira Aguilar, Patricia, et al.
Publicado: (2019)

Characterization of Alternative Promoters to Stagger and Control Protein Expression in the Baculovirus-Insect Cell System: From Intracellular Reporter Proteins to Fluorescent Influenza Virus-like Particles
por: George, Steve, et al.
Publicado: (2015)

Characterisation of a spumavirus Gag protein
por: Goldstone, David C, et al.
Publicado: (2013)

Early presentation of HIV-1 KF11Gag and KK10Gag protective epitopes facilitate rapid CD8+ T cell activation and killing of virus infected cells
por: Kløverpris, HN, et al.
Publicado: (2012)

Dynamics and frequency of Gag transmitted polymorphisms in Zambia
por: Schaefer, M, et al.
Publicado: (2012)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2023)

Post-transcriptional control of HIV-1 Gag expression
por: Phalora, Prabhjeet, et al.
Publicado: (2013)

Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles
por: Kessans, Sarah A., et al.
Publicado: (2016)

Functional analyses of glycosylated gag molecules derived from different gammaretroviruses
por: Cuccurullo, Emilia Cristiana, et al.
Publicado: (2013)

Generation of virus-like particle as a vaccine strategy against bovine leukemia virus
por: Otsuki, Hiroyuki, et al.
Publicado: (2015)

Preferential targeting of co-evolving Gag residues in long-term non progressors
por: Sunshine, J, et al.
Publicado: (2012)

Endogenous retrovirus type W GAG and ENV antigenaemia in serum of schizophrenic patients
por: Bernard, Corinne, et al.
Publicado: (2009)

Expression of Gag and Pol from reconstructed HERV-Fc1, associated with multiple sclerosis
por: Nissen, Kari K, et al.
Publicado: (2011)

P04-32. Differential regulation of secondary antibody responses to Gag and Env proteins
por: Nabi, G, et al.
Publicado: (2009)

Integrating nanoparticle quantification and statistical design of experiments for efficient HIV-1 virus-like particle production in High Five cells
por: Puente-Massaguer, Eduard, et al.
Publicado: (2020)

Epitope mapping of CD8+ T cells on bovine leukemia virus Gag, Env and Tax protein in cattle with different bovine MHC DRB3 alleles
por: Bai, Lanlan, et al.
Publicado: (2015)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

Dissecting the contribution of Gag domain in resistance development in HIV-1 patients failing ARV therapy
por: Carli, Ilaria, et al.
Publicado: (2013)

N-terminal foamy virus Gag domains and individual residues are critical for capsid assembly and interaction with the unique Env leader protein Elp for Env-dependent budding
por: Liu, Yang, et al.
Publicado: (2013)

Formation of virus-like particles from human cell lines exclusively expressing Influenza Neuraminidase
por: Lai, JCC, et al.
Publicado: (2011)

Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana
por: Kessans, Sarah A, et al.
Publicado: (2013)

P20-12. Heterogeneity of Gag mutational pathways in primary HIV-1 subtype C infection
por: Novitsky, V, et al.
Publicado: (2009)

Development of a Plasmodium vivax malaria vaccine for clinical applications using transgenic parasites, virus-like particles and recombinant viruses
por: Reyes-Sandoval, Arturo, et al.
Publicado: (2014)

The role of murine leukemia virus glycosated Gag protein in virus replication
por: Fan, Hung
Publicado: (2011)

P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles
por: Tagliamonte, M, et al.
Publicado: (2009)

Gag-Vpu cross talk modulating HIV-1 envelope incorporation and infectivity in cell-type dependent manner
por: Gautam, Archana, et al.
Publicado: (2012)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Limited evidence for alterations in Gag-mediated HIV replication capacity over the course of the North American epidemic (1979-present)
por: Cotton, L, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lu7f2bfgm1nhv79j0p3dfgg9rt